L3VLUP
ProSign in

MXCT · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

MXCTLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • MXCT
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterMXCTLLY
Q3 2020none listed holders, n.a.33 holders, $14.1bn
Q4 2020none listed holders, n.a.29 holders, $17.3bn
Q1 2021none listed holders, n.a.24 holders, $23.0bn
Q2 2021none listed holders, n.a.24 holders, $27.8bn
Q3 20213 holders, $110m31 holders, $29.9bn
Q4 20213 holders, $96m31 holders, $34.7bn
Q1 20223 holders, $54m24 holders, $35.3bn
Q2 20222 holders, $20m33 holders, $42.7bn
Q3 20223 holders, $29m31 holders, $43.4bn
Q4 20223 holders, $23m31 holders, $46.6bn
Q1 20234 holders, $18m33 holders, $44.3bn
Q2 20232 holders, $15m37 holders, $59.6bn
Q3 20231 holders, $6.6m44 holders, $67.6bn
Q4 2023none listed holders, n.a.45 holders, $73.6bn
Q1 2024none listed holders, n.a.41 holders, $95.3bn
Q2 2024none listed holders, n.a.43 holders, $110bn
Q3 2024none listed holders, n.a.45 holders, $107bn
Q4 2024none listed holders, n.a.46 holders, $93.9bn
Q1 2025none listed holders, n.a.42 holders, $98.4bn
Q2 2025none listed holders, n.a.43 holders, $93.2bn
Q3 2025none listed holders, n.a.39 holders, $86.7bn
Q4 2025none listed holders, n.a.41 holders, $123bn
Q1 2026none listed holders, n.a.39 holders, $106bn
Q2 2026none listed holders, n.a.44 holders, $132bn
MXCT

Maxcyte Inc

Holders
0
Reported value
$0
Buyers
n.a.
Sellers
n.a.

No cross-section for this quarter.

Health care services and researchHealthcare: biopharma and medtech · L3VLUP
LLY

Eli Lilly & Co

Holders
43
Reported value
$93.2bn
Buyers
25
Sellers
22

Breadth +3 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2025

Among the 43 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Both (0)

No tracked manager lists every one of them.

Only MXCT (0)

None.

Only LLY (43)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Artisan Partners LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, Coatue Management LLC, D. E. Shaw & Co., Dodge & Cox, Eisler Capital Management Ltd, ExodusPoint Capital Management LP, Fidelity (FMR LLC), Freestone Grove Partners LP, GAMCO Investors Inc, Harris Associates LP, Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Maverick Capital Ltd, and 18 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →